AnaptysBio, Inc. (NASDAQ:ANAB) Receives $79.18 Average PT from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has received an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $79.1818.

ANAB has been the subject of a number of research analyst reports. Stifel Nicolaus boosted their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. UBS Group boosted their target price on shares of AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Leerink Partners set a $90.00 target price on shares of AnaptysBio in a research report on Friday, May 15th. Zacks Research raised shares of AnaptysBio from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of AnaptysBio in a research report on Monday, March 30th.

Insider Transactions at AnaptysBio

In other news, CEO Daniel Faga sold 17,679 shares of the company’s stock in a transaction dated Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the transaction, the chief executive officer owned 495,965 shares of the company’s stock, valued at approximately $30,556,403.65. This represents a 3.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John P. Schmid sold 20,645 shares of the company’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the transaction, the director directly owned 31,622 shares of the company’s stock, valued at $1,774,310.42. This represents a 39.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 33.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC raised its position in shares of AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares during the last quarter. Larson Financial Group LLC raised its position in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 473 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in AnaptysBio by 24.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 263 shares in the last quarter. Bessemer Group Inc. raised its position in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in AnaptysBio by 940.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 1,383 shares in the last quarter.

AnaptysBio Price Performance

AnaptysBio stock opened at $59.71 on Thursday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -55.29 and a beta of 0.79. AnaptysBio has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The firm has a fifty day moving average price of $62.71 and a two-hundred day moving average price of $52.80.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The firm had revenue of $25.56 million for the quarter, compared to analyst estimates of $18.86 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 11.53%. As a group, sell-side analysts expect that AnaptysBio will post -1.8 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has approved a share buyback plan on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in shares. This buyback authorization authorizes the biotechnology company to reacquire up to 5,352,316.2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.